New Stroke Prevention Drug Shows Safer Protection Beyond Aspirin

A large international trial suggests factor XIa inhibition may reduce recurrent stroke risk without increasing bleeding

A major clinical trial suggests the factor XIa inhibitor asundexian may reduce recurrent ischemic stroke risk by about 25% without increasing major bleeding, offering a potential shift beyond traditional aspirin-based prevention strategies.

Study Details

Secondary stroke prevention has long relied on antiplatelet therapies like aspirin, which offer modest…